Similarly, use of an SGLT-2 inhibitor was associated with a lower incidence of cardiovascular death in patients without CKD: RR 0.85 (95% CI 0.73–0.99; P = 0.04) (Fig. 1 and Table 3). This evidence concerns the gene SLC5A2 and chronic kidney disease.